Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis

References

• GeilerJBuchMMcDermottMFAnti-TNF treatment in rheumatoid arthritisCurr Pharm Des201117293141315421864263
   PubMed Web of Science ®Google Scholar
• LinJZiringDDesaiSTNFalpha blockade in human diseases: an overview of efficacy and safetyClin Immunol20081261133017916445
   PubMed Web of Science ®Google Scholar
• AliTKaithaSMahmoodSFtesiAStoneJBronzeMSClinical use of anti-TNF therapy and increased risk of infectionsDrug Healthc Patient Saf20135799923569399
   PubMedGoogle Scholar
• KievitWFransenJOerlemansAThe efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practiceAnn Rheum Dis200766111473147817426065
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonAJSweetingMJBuchanIMattesonELMontoriVAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJAMA2006295192275228516705109
   PubMed Web of Science ®Google Scholar
• SalliotCGossecLRuyssen-WitrandAInfections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patientsRheumatology (Oxford)200746232733416880188
   PubMed Web of Science ®Google Scholar
• KomanoYTanakaMNankiTIncidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm SafetyJ Rheumatol20113871258126421498482
   PubMed Web of Science ®Google Scholar
• GallowayJBMercerLKMoseleyARisk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterAnn Rheum Dis201372222923422532633
   PubMed Web of Science ®Google Scholar
• LeombrunoJPEinarsonTRKeystoneECThe safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse eventsAnn Rheum Dis20096871136114518753157
   PubMed Web of Science ®Google Scholar
• Peyrin-BirouletLDeltenrePDe SurayNBrancheJSandbornWJColombelJFEfficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trialsClin Gastroenterol Hepatol20086664465318550004
   PubMed Web of Science ®Google Scholar
• Fouque-AubertAJette-PaulinLCombescureCBaschATebibJGossecLSerious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trialsAnn Rheum Dis201069101756176119640854
   PubMed Web of Science ®Google Scholar
• WongMZiringDKorinYTNFalpha blockade in human diseases: mechanisms and future directionsClin Immunol2008126212113617916444
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJCarmonaLAngel DescalzoMRisk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infectionArthritis Rheum200757575676117530674
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJCarmonaLValverdeVRMolaEMMonteroMDTreatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance reportArthritis Rheum20034882122212712905464
   PubMed Web of Science ®Google Scholar
• Jauregui-AmezagaATuronFOrdasIRisk of developing tuberculosis under anti-TNF treatment despite latent infection screeningJ Crohns Colitis20137320821222677117
   PubMed Web of Science ®Google Scholar
• WinthropKLBaxterRLiuLMycobacterial diseases and anti-tumour necrosis factor therapy in USAAnn Rheum Dis2013721374222523429
   PubMed Web of Science ®Google Scholar
• ZarHJMadhiSAAstonSJGordonSBPneumonia in low and middle income countries: progress and challengesThorax201368111052105623956020
   PubMed Web of Science ®Google Scholar
• MurrayCJStybloKRouillonATuberculosis in developing countries: burden, intervention and costBull Int Union Tuberc Lung Dis19906516242190653
   PubMedGoogle Scholar
• PittetDAllegranziBStorrJInfection control as a major World Health Organization priority for developing countriesJ Hosp Infect200868428529218329137
   PubMed Web of Science ®Google Scholar
• KimSYServiAPolinskiJMValidation of rheumatoid arthritis diagnoses in health care utilization dataArthritis Res Ther2011131R3221345216
   PubMed Web of Science ®Google Scholar
• PalladinoMABahjatFRTheodorakisEAMoldawerLLAnti-TNF-α therapies: the next generationNat Rev Drug Discov20032973674612951580
   PubMed Web of Science ®Google Scholar
• DanielTKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther2008117224427918155297
   PubMed Web of Science ®Google Scholar
• ClayHVolkmanHERamakrishnanLTumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage deathImmunity200829228329418691913
   PubMed Web of Science ®Google Scholar
• DoranMFCrowsonCSPondGRO’FallonWMGabrielSEFrequency of infection in patients with rheumatoid arthritis compared with controls: a population-based studyArthritis Rheum20024692287229312355475
   PubMed Web of Science ®Google Scholar
• JohnstonSSTurpcuAShiNFowlerRChuBCAlexanderKRisk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysisSemin Arthritis Rheum2013431394723453683
   PubMed Web of Science ®Google Scholar
• GallowayJBHyrichKLMercerLKAnti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology (Oxford)201150112413120675706
   PubMed Web of Science ®Google Scholar
• Van DartelSAFransenJKievitWPredictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registryRheumatology20135261052105723365147
   PubMed Web of Science ®Google Scholar
• HammoudehMAlarfajAChenDYDjoudiHYouseifEZhuJSafety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosisClin Rheumatol201332329330023242389
   PubMed Web of Science ®Google Scholar
• KroesenSWidmerAFTyndallAHaslerPSerious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapyRheumatology (Oxford)200342561762112709536
   PubMed Web of Science ®Google Scholar
• LaneMAMcDonaldJRZeringueALTNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisMedicine (Baltimore)201190213914521358439
   PubMed Web of Science ®Google Scholar
• TohSLiLHarroldLRComparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Pharmacoepidemiol Drug Saf201221552453422411435
   PubMed Web of Science ®Google Scholar
• GrijalvaCGChenLDelzellEInitiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseasesJAMA2011306212331233922056398
   PubMed Web of Science ®Google Scholar
• CurtisJRXiJPatkarNXieASaagKGMartinCDrug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonistsArthritis Rheum200756124226422718050253
   PubMed Web of Science ®Google Scholar
• GrijalvaCGKaltenbachLArbogastPGMitchelEFJrGriffinMRInitiation of rheumatoid arthritis treatments and the risk of serious infectionsRheumatology (Oxford)2010491829019906833
   PubMed Web of Science ®Google Scholar
• CurtisJRXieFChenLThe comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsAnn Rheum Dis20117081401140621586439
   PubMed Web of Science ®Google Scholar
• AsklingJForedCMBrandtLTime-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnn Rheum Dis200766101339134417261532
   PubMed Web of Science ®Google Scholar
• KumarAExperience with anti-tumor necrosis factor-α therapy in IndiaAPLAR Journal of Rheumatology200692136141
   Google Scholar
• WallisRBroderMWongJHansonMBeenhouwerDGranulomatous infectious diseases associated with tumor necrosis factor antagonistsClin Infect Dis20043891261126515127338
   PubMed Web of Science ®Google Scholar
• DixonWGHyrichKLWatsonKDDrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Ann Rheum Dis201069352252819854715
   PubMed Web of Science ®Google Scholar
• Public Health Agency of CanadaInternational tuberculosis incidence rates2011 Available from: http://www.phac-aspc.gc.ca/tbpc-latb/itir-eng.phpAccessed February 25, 2014
   Google Scholar
• SellamJHamdiHRoyCComparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapyAnn Rheum Dis200766121610161517456528
   PubMed Web of Science ®Google Scholar
• DielRDGolettiGFerraraGInterferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysisEur Respir J201131889921030451
   PubMed Web of Science ®Google Scholar
• SesterMSotgiuGLangeCInterferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysisEur Respir J201137110011120847080
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med20013451510991104
   Web of Science ®Google Scholar
• Hajjaj-HassouniNAl-BadiMAl-EmadiSThe practical value of biologics registries in Africa and Middle East: challenges and opportunitiesClin Rheum2012313407416
   Web of Science ®Google Scholar